Boehringer Ingelheim International GmbH
Kim Brodovicz is the Inflammation Group Head in Global Epidemiology and Real World Evidence at Boehringer Ingelheim.
Kim has been with BI for close to 7 years and has supported drugs and vaccines from early development to post-approval in a variety of therapeutic areas and has conducted numerous epidemiology studies using existing data and new data collection over her more than 20 years in industry. Prior to joining industry, Kim was an infectious disease epidemiologist at the Philadelphia Department of Public Health. Kim received her DrPH in epidemiology from the Johns Hopkins Bloomberg School of Public Health, a MPH in infectious disease epidemiology from Yale University School of Medicine, and BA in Medical Anthropology from the University of Pennsylvania.
Tuesday, August 24, 2021
11:45 AM – 1:15 PM US Eastern Time
Wednesday, August 25, 2021
4:30 PM – 6:00 PM US Eastern Time